Publications by authors named "Gianni Micucci"
Article Synopsis
- Peripheral blasts (PB) in myelofibrosis patients are linked to worse outcomes, with PB levels of 4% or higher significantly impacting prognosis.
- A study of 794 chronic-phase myelofibrosis patients treated with ruxolitinib (RUX) found that those with higher PB percentages had poorer responses in spleen size reduction and overall survival compared to those without PB.
- The findings suggest that patients with higher PB levels may benefit from treatment strategies that go beyond standard RUX therapy.
